Discontinued — last reported Q4 '24

Operating

Net gains (losses) on investments

United Therapeutics Net gains (losses) on investments decreased by 1062.3% to -$61.60M in Q1 2026 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementCash Flow Statement
SectionOperating
CategoryCapital Allocation
SignalHigher is better
VolatilityVolatile
First reportedQ1 2018
Last reportedQ4 2024

How to read this metric

Positive values indicate successful investment management, while negative values reflect market volatility or poor asset performance.

Detailed definition

This captures the non-cash gains or losses realized from the sale or revaluation of equity investments and securities. I...

Peer comparison

Common for large corporations with diversified portfolios or strategic minority stakes.

Metric ID: gain_loss_on_investments

Historical Data

2 periods
 Q1 '25Q1 '26
Value-$5.30M-$61.60M
QoQ Change—<-999%
YoY Change—<-999%
Range-$61.60M – -$5.30M
Avg YoY Growth<-999%
Median YoY Growth<-999%

Net gains (losses) on investments at Other Companies

ALN
Alnylam PharmaceuticalsALNYView metric
Amgen logo
AmgenAMGNView metric
Biogen logo
BiogenBIIBView metric

Frequently Asked Questions

What is United Therapeutics's net gains (losses) on investments?
United Therapeutics (UTHR) reported net gains (losses) on investments of -$61.60M in Q1 2026.
What does net gains (losses) on investments mean?
The profit or loss made from selling or holding financial investments.